Tag: GLP-1 receptor agonist (exendin-4)

  • Exenatide

    GLP-1 receptor agonist (exendin-4)

    A synthetic version of the Gila monster venom peptide exendin-4, FDA-approved as Byetta (twice daily) and Bydureon (weekly) for T2DM.

    Abstract

    Exenatide (Byetta, Bydureon; CAS 141758-74-9; molecular weight 4186.57) is a synthetic version of exendin-4, a 39-amino-acid peptide originally isolated from Gila monster (Heloderma suspectum) venom. The compound is a GLP-1 receptor agonist with substantial structural difference from human GLP-1, providing resistance to DPP-4 cleavage. Exenatide was the first GLP-1 receptor agonist approved (Byetta, 2005); the extended-release formulation (Bydureon, 2012) provides once-weekly administration.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.